Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing.
The etiological agent of the COVID-19 pandemic is SARS-CoV-2. As a member of the Coronaviridae, the enveloped pathogen has several membrane proteins, of which two, E and 3a, were suggested to function as ion channels. In an effort to increase our treatment options, alongside providing new research tools, we have sought to inhibit the 3a channel by targeted drug repurposing. To that end, using three bacteria-based assays, we screened a library of 2839 approved-for-human-use drugs and identified the following potential channel-blockers: Capreomycin, Pentamidine, Spectinomycin, Kasugamycin, Plerixafor, Flumatinib, Litronesib, Darapladib, Floxuridine and Fludarabine. The stage is now set for examining the activity of these compounds in detailed electrophysiological studies and their impact on the whole virus with appropriate biosafety measures.
['Tomar|Prabhat Pratap Singh|PPS|0000-0002-5729-7066', 'Krugliak|Miriam|M|', 'Arkin|Isaiah T|IT|0000-0002-7659-1746']
D000998:Antiviral Agents D000086382:COVID-19 D004353:Drug Evaluation, Preclinical D058492:Drug Repositioning D006801:Humans D000086402:SARS-CoV-2 D014759:Viral Envelope Proteins D000086082:Viroporin Proteins
antiviral drugs bacterial assays channel blockers viral channels